Plaque Psoriasis – Comprehensive Medical Guide

Overview

Plaque psoriasis (also called psoriasis vulgaris) is a chronic, immune‑mediated skin disorder characterized by well‑defined, raised, red patches covered with silvery‑white scales. It is the most common form of psoriasis, accounting for about 80‑90 % of all cases.

• Who it affects: It can occur at any age, but onset most often happens between ages 15‑35 and again around 50‑60. Both sexes are equally affected.
• Prevalence: Worldwide, roughly 2–3 % of the population (about 125 million people) have psoriasis, and up to 90 % of those have the plaque type.^{[1] Mayo Clinic}
• Geography: Higher rates are reported in Caucasian populations (up to 3 %); lower rates in Asian and African populations, though prevalence is rising globally.

Symptoms

Symptoms vary from mild, localized lesions to extensive body‑surface involvement. Common features include:

Skin lesions

• Red (erythematous) plaques: Well‑demarcated, raised patches that may be itchy or painful.
• Silvery‑white scale: Thick, flaky surface that can bleed if scratched.
• Location: Frequently appears on elbows, knees, scalp, lower back, and navel; can affect any skin area, including the hands, feet, and genitals.

Other skin‑related findings

• Koebner phenomenon – new plaques develop at sites of trauma (scratches, surgical scars).
• Pustular psoriasis – white pustules surrounded by red skin, usually a separate subtype but can coexist.
• Guttate psoriasis – small drop‑shaped lesions that may appear after streptococcal infection.

Systemic symptoms

• Fatigue, especially in moderate‑to‑severe disease.
• Joint pain or stiffness suggestive of psoriatic arthritis (affects ~30 % of plaque psoriasis patients).^{[2] NIH}

Psychosocial impact

• Depression, anxiety, and reduced quality of life are common, especially when lesions are visible.

Causes and Risk Factors

Psoriasis is not contagious. It results from a complex interaction of genetics, immune dysregulation, and environmental triggers.

Genetic factors

• More than 80 % of patients have a first‑degree relative with psoriasis.
• Multiple susceptibility genes identified, especially HLA‑Cw6 on chromosome 6p21.

Immune system dysfunction

Overactive T‑cells release cytokines (TNF‑α, IL‑17, IL‑23) that accelerate skin cell turnover, leading to plaque formation.

Environmental triggers

• Infections: Streptococcal throat infections can precipitate guttate lesions that later evolve into plaque psoriasis.
• Trauma: Cuts, scrapes, sunburn, or surgical scars (Koebner phenomenon).
• Medications: Lithium, β‑blockers, antimalarials, and interferon‑α.
• Stress: Psychological stress can flare disease.
• Smoking & alcohol: Both increase risk and severity.^{[3] CDC}

Risk factors

• Positive family history.
• Obesity (BMI ≥ 30) – adipose tissue produces inflammatory cytokines.
• Metabolic syndrome, diabetes, and cardiovascular disease.
• Age < 30 years (early onset tends to be more severe).

Diagnosis

Diagnosis is primarily clinical, based on visual examination and patient history.

Physical examination

• Characteristic plaques with silvery scale.
• Assessment of body‑surface area using the Psoriasis Area and Severity Index (PASI) or simpler rule of nines.

Dermatological tools

• Dermoscopy: Non‑invasive magnification to evaluate scaling patterns.
• Skin biopsy: Reserved for atypical lesions; histology shows hyperkeratosis, parakeratosis, and elongated rete ridges.

Laboratory tests (to assess comorbidities)

• Complete blood count, liver function tests, and renal panel (baseline before systemic therapy).
• Lipid profile and fasting glucose (psoriasis is linked to metabolic disease).
• Screening for hepatitis B/C and tuberculosis before biologic agents.

Treatment Options

Treatment is individualized based on severity, affected area, comorbidities, and patient preferences. Goals are to clear or markedly reduce plaques, control symptoms, and improve quality of life.

Topical therapies (first‑line for mild‑moderate disease)

• Corticosteroids: Low‑ to high‑potency creams or ointments; limit use to < 2 weeks for potent steroids to avoid skin atrophy.
• Vitamin D analogues: Calcipotriene, calcitriol – reduce keratinocyte proliferation.
• Combination products: Steroid + vitamin D (e.g., betamethasone/calcipotriene). Proven more effective than either alone.^{[4] Cleveland Clinic}
• Retinoids: Tazarotene – helps in resistant plaques.
• Coal tar & salicylic acid: Useful for scalp psoriasis.

Phototherapy (moderate disease)

• NB‑UVB (narrow‑band UVB): 3‑5 sessions per week; 12‑20 weeks often leads to 70–80 % improvement.
• Excimer laser (308 nm): Targets limited areas.
• Contraindications: History of skin cancer or photosensitivity.

Systemic oral medications (moderate‑severe disease)

• Methotrexate: First‑line immunosuppressant; dose 7.5–25 mg weekly. Monitor liver enzymes and blood counts.
• Acitretin: Oral retinoid; teratogenic – strict contraception required for women of childbearing age.
• Ciclosporin: Potent immunosuppressant; used for rapid control, limited to < 12 months due to nephrotoxicity.

Biologic agents (moderate‑severe or refractory disease)

Target	Examples	Typical dosing
TNF‑α inhibitors	Etanercept, Adalimumab, Infliximab	Subcutaneous or IV every 1‑2 weeks
IL‑12/23 inhibitor	Ustekinumab	Injection at weeks 0, 4, then every 12 weeks
IL‑17 inhibitors	Secukinumab, Ixekizumab, Brodalumab	Loading dose then every 4 weeks
IL‑23 inhibitors	Guselkumab, Risankizumab, Tildrakizumab	Every 8‑12 weeks after loading

Biologics have the highest efficacy (≥ 90 % of patients achieve PASI 75) but require screening for infections and routine monitoring.^{[5] WHO}

Adjunctive lifestyle measures

• Moisturize daily with fragrance‑free emollients to reduce scaling.
• Weight reduction (5–10 % loss) improves response to therapy.
• Quit smoking and limit alcohol intake.
• Stress‑reduction techniques (mindfulness, CBT, yoga).

Living with Plaque Psoriasis

Effective self‑management can lessen flare‑ups and improve wellbeing.

Skin‑care routine

• Take lukewarm showers; avoid harsh soaps.
• Apply a thick moisturizer within 3 minutes of bathing to lock in moisture.
• Use sunscreen (SPF 30+) daily; UVB can aggravate some lesions.

Clothing & daily activities

• Choose soft, breathable fabrics (cotton, bamboo).
• Avoid tight sleeves or belts that create friction.
• Protect scalp lesions with a gentle, medicated shampoo.

Psychological support

• Join support groups (online or local).
• Consider counseling if you experience depression or anxiety.
• Patient‑education apps (e.g., MyPsoriasisTeam) can track triggers.

Monitoring for comorbidities

• Annual cardiovascular risk assessment (blood pressure, lipids).
• Screen for psoriatic arthritis: joint pain, stiffness, swelling.
• Routine eye exams if you have ocular involvement (e.g., uveitis).

Prevention

While you cannot prevent a genetic predisposition, certain measures can lower the chance of developing plaque psoriasis or reduce flare frequency.

• Maintain a healthy weight: Obesity increases inflammatory load.
• Avoid smoking and limit alcohol: Dose‑dependent risk.
• Prompt treatment of skin injuries: Reduce Koebner phenomenon.
• Manage stress: Mindfulness, exercise, adequate sleep.
• Vaccinations: Keep flu and COVID‑19 vaccines up‑to‑date; infections can trigger flares.

Complications

If left inadequately treated, plaque psoriasis can lead to several medical and psychosocial complications.

• Psoriatic arthritis: Progressive joint damage, may require DMARDs.
• Cardiovascular disease: 1.5‑2 × higher risk of myocardial infarction and stroke.^{[6] NIH}
• Metabolic syndrome: Higher prevalence of type 2 diabetes and dyslipidemia.
• Psychiatric illness: Depression rates up to 30 % in severe disease.
• Skin infections: Cracked plaques are portals for bacterial (Staph aureus) and fungal infections.
• Rare malignancies: Long‑term immunosuppressive therapy slightly raises skin‑cancer risk; regular skin checks are advised.

When to Seek Emergency Care

---

References:
[1] Mayo Clinic. “Psoriasis”. https://www.mayoclinic.org
[2] National Institutes of Health (NIH). “Psoriatic Arthritis”. https://www.niams.nih.gov
[3] Centers for Disease Control and Prevention (CDC). “Psoriasis”. https://www.cdc.gov
[4] Cleveland Clinic. “Topical Treatments for Psoriasis”. https://my.clevelandclinic.org
[5] World Health Organization (WHO). “Biologic Therapies for Psoriasis”. https://www.who.int
[6] NIH. “Psoriasis and Cardiovascular Risk”. https://www.nhlbi.nih.gov